$80.39
Intracellular Th is a drug manufacturers - specialty & generic business based in the US. Intracellular Th shares (ITCI) are listed on the NASDAQ and all prices are listed in US Dollars. Intracellular Th employs 610 staff and has a trailing 12-month revenue of around $513.9 million.
Our top picks for where to buy Intracellular Th stock
How to buy Intracellular Th stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ITCI. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Intracellular Th stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Intracellular Th stock price (NASDAQ: ITCI)
Use our graph to track the performance of ITCI stocks over time.Intracellular Th shares at a glance
Latest market close | $80.84 |
---|---|
52-week range | $45.50 - $84.89 |
50-day moving average | $70.03 |
200-day moving average | $65.86 |
Wall St. target price | $93.31 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.16 |
Is it a good time to buy Intracellular Th stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Intracellular Th price performance over time
Historical closes compared with the close of $80.84 from 2024-07-25
1 week (2024-07-19) | 7.99% |
---|---|
1 month (2024-06-27) | 13.89% |
3 months (2024-04-26) | 10.35% |
6 months (2024-01-26) | 19.99% |
1 year (2023-07-27) | 30.47% |
---|---|
2 years (2022-07-27) | 51.13% |
3 years (2021-07-27) | 136.79% |
5 years (2019-07-26) | 865.83% |
Intracellular Th financials
Revenue TTM | $513.9 million |
---|---|
Gross profit TTM | $95.2 million |
Return on assets TTM | -11.23% |
Return on equity TTM | -18.07% |
Profit margin | -21.57% |
Book value | $6.15 |
Market Capitalization | $7.9 billion |
TTM: trailing 12 months
Intracellular Th share dividends
We're not expecting Intracellular Th to pay a dividend over the next 12 months.
Intracellular Th share price volatility
Over the last 12 months, Intracellular Th's shares have ranged in value from as little as $45.5 up to $84.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intracellular Th's is 1.007. This would suggest that Intracellular Th's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Intracellular Th overview
Intra-Cellular Therapies, Inc. , a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Frequently asked questions
What percentage of Intracellular Th is owned by insiders or institutions?Currently 2.339% of Intracellular Th shares are held by insiders and 89.478% by institutions. How many people work for Intracellular Th?
Latest data suggests 610 work at Intracellular Th. When does the fiscal year end for Intracellular Th?
Intracellular Th's fiscal year ends in December. Where is Intracellular Th based?
Intracellular Th's address is: 430 East 29th Street, New York, NY, United States, 10016 What is Intracellular Th's ISIN number?
Intracellular Th's international securities identification number is: US46116X1019 What is Intracellular Th's CUSIP number?
Intracellular Th's Committee on Uniform Securities Identification Procedures number is: 46116X101
More guides on Finder
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
Put options explained
Learn the basics of put options: what they are, how they work and a few examples.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
11 apps like Webull you need to consider
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question